By Ethan Covey
Adults living with HIV who initiated therapy with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) (Biktarvy, Gilead) and continued through five years of follow-up demonstrated high rates of virologic suppression, CD4 recovery and no treatment-related resistance, regardless of baseline viral load and CD4 count. These findings come from pooled data from two phase 3 clinical trials presented at IDWeek 2022 (poster 1251) in Washington, D.C.
“People with HIV at